Open AccessAntiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
Author(s) -
John M. Murray,
Sean Emery,
Anthony D. Kelleher,
Matthew Law,
Joshua Chen,
Daria J. Hazuda,
BachYen Nguyen,
Hedy Teppler,
David A. Cooper
Publication year - 2007
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3282f12377
Subject(s) - raltegravir , integrase inhibitor , integrase , efavirenz , virology , elvitegravir , viral load , lamivudine , pharmacology , biology , medicine , virus , antiretroviral therapy , human immunodeficiency virus (hiv) , hepatitis b virus
Raltegravir (MK-0518) belongs to the new class of HIV integrase inhibitors. To date, there have been no reports investigating the potential for differential effects on viral dynamics with integrase inhibitors relative to current antiretroviral drugs.